Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.

De S, Lindner DJ, Coleman CJ, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 May 1;78(9):2396-2406. doi: 10.1158/0008-5472.CAN-17-1920. Epub 2018 Feb 13.

PMID:
29440145
2.

Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis.

Asano K, Nelson CM, Nandadasa S, Aramaki-Hattori N, Lindner DJ, Alban T, Inagaki J, Ohtsuki T, Oohashi T, Apte SS, Hirohata S.

Sci Rep. 2017 Dec 8;7(1):17225. doi: 10.1038/s41598-017-17613-6.

3.

Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer.

Zamanian-Daryoush M, Lindner DJ, DiDonato JA, Wagner M, Buffa J, Rayman P, Parks JS, Westerterp M, Tall AR, Hazen SL.

Oncotarget. 2017 Jun 27;8(42):71965-71980. doi: 10.18632/oncotarget.18666. eCollection 2017 Sep 22.

4.

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.

Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, Parker Y, Lindner DJ, Nagaraj AB, Kim JJ, DiFeo A, Abdul-Karim FW, Michener C, Rose PG, DeBernardo R, Mahdi H, McCrae KR, Lin F, Lathia JD, Reizes O.

J Exp Med. 2017 Sep 4;214(9):2715-2732. doi: 10.1084/jem.20170438. Epub 2017 Aug 24.

5.

Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1-Mediated Macrophage Infiltration.

Sossey-Alaoui K, Pluskota E, Bialkowska K, Szpak D, Parker Y, Morrison CD, Lindner DJ, Schiemann WP, Plow EF.

Cancer Res. 2017 Sep 15;77(18):5129-5141. doi: 10.1158/0008-5472.CAN-16-2337. Epub 2017 Jul 7.

PMID:
28687620
6.

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.

Br J Cancer. 2016 Oct 11;115(8):920-928. doi: 10.1038/bjc.2016.263. Epub 2016 Aug 25.

7.

Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.

Vatolin S, Phillips JG, Jha BK, Govindgari S, Hu J, Grabowski D, Parker Y, Lindner DJ, Zhong F, Distelhorst CW, Smith MR, Cotta C, Xu Y, Chilakala S, Kuang RR, Tall S, Reu FJ.

Cancer Res. 2016 Jun 1;76(11):3340-50. doi: 10.1158/0008-5472.CAN-15-3099. Epub 2016 Apr 6.

8.

RNase L is a negative regulator of cell migration.

Banerjee S, Li G, Li Y, Gaughan C, Baskar D, Parker Y, Lindner DJ, Weiss SR, Silverman RH.

Oncotarget. 2015 Dec 29;6(42):44360-72. doi: 10.18632/oncotarget.6246.

9.

Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.

Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ, Parker Y, Daneshgari F, Gupta S.

Mol Cancer Ther. 2014 Oct;13(10):2288-302. doi: 10.1158/1535-7163.MCT-14-0451. Epub 2014 Aug 13.

10.

Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis.

Sossey-Alaoui K, Pluskota E, Davuluri G, Bialkowska K, Das M, Szpak D, Lindner DJ, Downs-Kelly E, Thompson CL, Plow EF.

FASEB J. 2014 May;28(5):2260-71. doi: 10.1096/fj.13-244004. Epub 2014 Jan 27.

11.

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Tabarroki A, Lindner DJ, Visconte V, Zhang L, Rogers HJ, Parker Y, Duong HK, Lichtin A, Kalaycio ME, Sekeres MA, Mountantonakis SE, Heresi GA, Tiu RV.

Leukemia. 2014 Jul;28(7):1486-93. doi: 10.1038/leu.2014.5. Epub 2014 Jan 10.

PMID:
24406841
12.

Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice.

Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Munivenkatappa R, Lindner DJ, Fiskum GM, Kalvakolanu DV.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):E4213-22. doi: 10.1073/pnas.1303760110. Epub 2013 Oct 21.

13.

GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.

Kalakonda S, Nallar SC, Lindner DJ, Sun P, Lorenz RR, Lamarre E, Reddy SP, Kalvakolanu DV.

Oncogene. 2014 Jun 12;33(24):3195-204. doi: 10.1038/onc.2013.271. Epub 2013 Jul 15.

14.

Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.

Nallar SC, Kalakonda S, Lindner DJ, Lorenz RR, Lamarre E, Weihua X, Kalvakolanu DV.

J Biol Chem. 2013 Mar 15;288(11):7930-41. doi: 10.1074/jbc.M112.440610. Epub 2013 Feb 5.

15.

Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC.

Matrix Biol. 2013 Mar 11;32(2):123-32. doi: 10.1016/j.matbio.2012.11.010. Epub 2012 Nov 30.

16.

A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.

Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, Hsieh JT, Page P, Liu L, Lindner DJ, Acharya C, MacKerell AD Jr, Ficker E, Song J, Wang B.

PLoS One. 2012;7(8):e42120. doi: 10.1371/journal.pone.0042120. Epub 2012 Aug 15.

17.

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.

18.

Identification of an mRNP complex regulating tumorigenesis at the translational elongation step.

Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MC, Merrick WC, Howe PH.

Mol Cell. 2011 Feb 18;41(4):419-31. doi: 10.1016/j.molcel.2011.02.003.

19.

Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.

Kundu S, Fan K, Cao M, Lindner DJ, Tuthill R, Liu L, Gerson S, Borden E, Yi T.

Mol Cancer Ther. 2010 Aug;9(8):2287-96. doi: 10.1158/1535-7163.MCT-10-0159. Epub 2010 Aug 3.

20.

Identification and characterization of GRIM-1, a cell-death-associated gene product.

Hofmann ER, Nallar SC, Lin L, D'Cunha J, Lindner DJ, Weihua X, Kalvakolanu DV.

J Cell Sci. 2010 Aug 15;123(Pt 16):2781-91. doi: 10.1242/jcs.070250. Epub 2010 Jul 27.

21.

Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activity.

Nallar SC, Kalakonda S, Sun P, Ohmori Y, Hiroi M, Mori K, Lindner DJ, Kalvakolanu DV.

Am J Pathol. 2010 Aug;177(2):896-907. doi: 10.2353/ajpath.2010.091280. Epub 2010 Jul 1. Erratum in: Am J Pathol. 2014 Mar;184(3):878.

22.

Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.

Kundu S, Fan K, Cao M, Lindner DJ, Zhao ZJ, Borden E, Yi T.

J Immunol. 2010 Jun 1;184(11):6529-36. doi: 10.4049/jimmunol.0903562. Epub 2010 Apr 26.

23.

ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells.

Koo BH, Coe DM, Dixon LJ, Somerville RP, Nelson CM, Wang LW, Young ME, Lindner DJ, Apte SS.

Am J Pathol. 2010 Mar;176(3):1494-504. doi: 10.2353/ajpath.2010.090655. Epub 2010 Jan 21.

24.

Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma.

Morrison BH, Haney R, Lamarre E, Drazba J, Prestwich GD, Lindner DJ.

Oncogene. 2009 Jun 25;28(25):2383-92. doi: 10.1038/onc.2009.113. Epub 2009 May 11.

25.

GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring.

Sun P, Nallar SC, Kalakonda S, Lindner DJ, Martin SS, Kalvakolanu DV.

Oncogene. 2009 Mar 12;28(10):1339-47. doi: 10.1038/onc.2008.480. Epub 2009 Jan 19.

26.

Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.

Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2008 Dec;28(12):733-40. doi: 10.1089/jir.2008.0030.

PMID:
18937547
27.

Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling.

Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, Masci RK, Lee RM, Didonato JA, Lindner DJ.

PLoS One. 2007 Dec 12;2(12):e1313.

28.

Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.

Kalakonda S, Nallar SC, Gong P, Lindner DJ, Goldblum SE, Reddy SP, Kalvakolanu DV.

Am J Pathol. 2007 Oct;171(4):1352-68. Epub 2007 Sep 6.

29.

Tumor-suppressive activity of the cell death activator GRIM-19 on a constitutively active signal transducer and activator of transcription 3.

Kalakonda S, Nallar SC, Lindner DJ, Hu J, Reddy SP, Kalvakolanu DV.

Cancer Res. 2007 Jul 1;67(13):6212-20.

30.
31.

Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappaB activation.

Morrison BH, Bauer JA, Lupica JA, Tang Z, Schmidt H, DiDonato JA, Lindner DJ.

J Biol Chem. 2007 May 25;282(21):15349-56. Epub 2007 Mar 22.

32.

Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.

Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, Li W, Lindner DJ, Williams B, Xu Y.

Oncogene. 2007 May 3;26(20):2894-901. Epub 2006 Nov 27.

PMID:
17130843
33.

Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.

Thakkar SG, Peereboom D, Olencki T, Jacobs B, Elson P, Rybicki L, Lindner DJ, Borden EC.

J Interferon Cytokine Res. 2006 Nov;26(11):800-3.

PMID:
17115898
34.

Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

Li J, Lindner DJ, Farver C, Borden EC, Yi T.

Cancer Chemother Pharmacol. 2007 Aug;60(3):341-9. Epub 2006 Nov 14.

PMID:
17103170
35.

Human telomerase RNA degradation by 2'-5'-linked oligoadenylate antisense chimeras in a cell-free system, cultured tumor cells, and murine xenograft models.

Paranjape JM, Xu D, Kushner DM, Okicki J, Lindner DJ, Cramer H, Silverman RH, Leaman DW.

Oligonucleotides. 2006 Fall;16(3):225-38.

PMID:
16978086
36.

Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4.

Tang Z, Bauer JA, Morrison B, Lindner DJ.

Mol Cell Biol. 2006 Aug;26(15):5588-94.

37.

IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.

Taylor KL, Oates RK, Grane R, Leaman DW, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2006 May;26(5):353-61.

PMID:
16689662
38.

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.

Bioconjug Chem. 2006 Jan-Feb;17(1):179-88.

PMID:
16417267
39.

Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.

Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T.

J Immunol. 2005 Nov 15;175(10):7003-8.

40.
41.

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC.

Cell Death Differ. 2004 Aug;11(8):915-23.

42.

Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.

Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ.

J Biol Chem. 2003 Oct 10;278(41):39461-9. Epub 2003 Jul 24.

43.

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC.

Apoptosis. 2003 Jun;8(3):237-49. Review.

PMID:
12766484
44.

IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.

Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC, Lindner DJ.

J Interferon Cytokine Res. 2003 Jan;23(1):3-10.

PMID:
12639293
45.

Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.

Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T.

Mol Cancer Ther. 2002 Dec;1(14):1255-64.

46.

Anticancer activity of sodium stibogluconate in synergy with IFNs.

Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC.

J Immunol. 2002 Nov 15;169(10):5978-85.

47.

Thioredoxin reductase plays a critical role in IFN retinoid-mediated tumor-growth control in vivo.

Lindner DJ, Ma X, Hu J, Karra S, Kalvakolanu DV.

Clin Cancer Res. 2002 Oct;8(10):3210-8.

48.

Interferons as antiangiogenic agents.

Lindner DJ.

Curr Oncol Rep. 2002 Nov;4(6):510-4. Review.

PMID:
12354364
49.

Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.

Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM, Carnevale KA, Smith DJ, Drazba J, Seetharam B, Lindner DJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9.

50.

MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma.

Roy SK, Hu J, Meng Q, Xia Y, Shapiro PS, Reddy SP, Platanias LC, Lindner DJ, Johnson PF, Pritchard C, Pag├ęs G, Pouyssegur J, Kalvakolanu DV.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7945-50. Epub 2002 Jun 4.

Supplemental Content

Loading ...
Support Center